• Publications
  • Influence
In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
TLDR
The results demonstrate that GVH and GVL activities can be dissected, while non-separable effector cells which exhibit both activities do exist as well. Expand
Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
TLDR
Various types of experiments showed that efficient CD3 x CD19 BsAb-mediated cytolytic capacity was not dependent on expression of either of these surface proteins, which contrasts with normal major histocompatibility complex-restricted antigen-specific cytotoxicity and may be essential for effective in vivo application of this Bs Ab. Expand
The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
TLDR
This clonogenic assay shows the importance of repeated administration of CD3 x CD19 BsAb and IL-2 and offers the possibility to compare it with other therapies in B-cell malignancy and shows the number of T cells proved critical in lysis of ALL-B cells. Expand
Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations.
TLDR
The data suggest that passive-active immunisation against hepatitis B virus infection is well tolerated by neonates under 3 months of age and that both early and late active immunisation in combination with passive immunisation will result in excellent anti-HBs production. Expand
Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
TLDR
Combination treatment of IFN-α 9MU-α s.c. three times a week and atrasentan 10 mg once daily is tolerated and clinical activity, especially OS, and biomarkers in the view warrant further studies targeting the endothelin axis. Expand
Human leukocyte antigen patterns in a family with cervical cancer.
TLDR
No association between the HLA-haplotype pattern and carcinoma in situ appeared to be present, but this does not exclude some unexplained genetic susceptibility for cervical cancer in this family. Expand
Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
TLDR
Results show that fresh humanLeukaemia/lymphoma cells, freshly derived from active lymphoblastic leukaemia (ALL) as well as non-Hodgkin's lymphoma (NHL) patients, can be effectively killed in the presence of this BsAb by activated T cells. Expand
The biomarker serum S100B identifies responders and prolonged survival in stage IV melanoma.
TLDR
A stably normal or rapidly normalizing S100B identifies a patient group in stage IV melanoma with limited and favorable metastatic sites and prolonged survival that might benefit from intensive multi-modality treatment consisting of chemotherapy followed by surgery of (residual) metastases and immunotherapy to achieve durable CR. Expand